Dataset opportunity
Celonic — 监管记录数据集机会
Celonic 持有的中等规模监管记录数据集，可用于监管 RAG 和合规助手。
Score
62
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
49%
Action
合作（集团层面）
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market size (indicative estimate)
全球监管信息管理系统市场 = 2024 年为 22 亿美元，复合年增长率为 10.9%。
Lineage
How this lead was derived
The signal-first chain, end to end: recent external signals → qualified niche → resolved data-holder → site verification → scored opportunity. Every lead is explainable.
Concrete evidence this company actively cares about data — why it's ripe for the deal room.
- 📣Press / announcement
被 UHC 和 DZIF 选中进行单克隆抗体工艺开发和 GMP 生产
source ↗
Profile
Dataset profile
Type
监管记录数据集
Modality
文本
Sector
医疗保健
Volume
中等
Freshness
定期
Rarity
高（专有）
Accessibility
受限
Legal
混合所有权 — 许可权待明确
Buyer persona
RegTech 和合规人工智能供应商
Celonic 持有全面的监管记录数据集，数据模态为文本，包括业务记录、工业数据和监管申报。这些结构化且特定领域的数据为训练和支持监管 RAG 系统提供了必要的证据，使其能够准确解释和响应有关生物制药制造和合规的复杂查询。
在全球监管信息管理系统市场中，其商业价值显而易见，该市场在 2024 年的估值为22 亿美元，预计将以 10.9% 的复合年增长率增长。[4] 虽然访问需要克服数据所有权在客户和专有数据之间划分、严格的 GMP 环境以及客户保密协议等复杂性，但这个精心策划的数据集具有非凡的价值。它为人工智能买家提供了稀有且有力的资产，以掌握监管合规性，使访问权的谈判成为一项有价值的战略投资。⚠ 尽职调查（有价值的数据，可协商的访问权）：数据所有权在客户特定的分子数据和 Celonic 的专有流程/平台数据之间划分；严格的 GMP（良好生产规范）监管环境决定了数据完整性和访问权限；与生物技术/制药客户的保密协议限制了特定生产批次的共享。· 公司：J. Rettenmaier & Söhne (JRS Group) 的子公司。
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
这些证据共同证明 Celonic 持有详细说明下一代生物制品和 ATMP 的专有制造、质量控制和性能的稀有端到端数据集。这对于寻求构建能够应对复杂申报的先进监管 RAG 系统的 RegTech 和合规人工智能供应商来说，是一项关键资产。在全球价值超过 22 亿美元的监管信息管理市场中，这些真实世界的证据为训练在通常无法获得的专有流程和结果上的模型提供了显著的竞争优势。
See dimension details ↓- Dataset Specificity78
主导的“监管”，医疗保健行业，2 种特定类型
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity70
专有领域数据
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Dataset Volume52
3 个证据命中
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Dataset Freshness46
定期
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value74
适用于监管 RAG
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Buyer Demand90
人工智能买家需求旺盛，这得益于在快速增长的监管信息管理系统市场中实现合规自动化的需求，该市场正以 10.9% 的复合年增长率扩张。[4]
How strongly AI builders and companies are likely to want this data, based on market signals. - Legal Accessibility28
受限/未知
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility0
高难度，J. Rettenmaier & Söhne (JRS Group) 的子公司
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Evidence Strength62
3 种证据类型，3 次命中
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Right to License36
所有权=混合，许可=权利不明确
Whether the company can legally license the data out — based on ownership and licensing complexity. - Corporate Independence50
J. Rettenmaier & Söhne (JRS Group) 的子公司
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group. - Data Orientation39
1 个数据需求信号（1 种类型）
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - Dormant Data Surplus92
盈余=高 — 专有数据超出已货币化的部分
Volume and value of proprietary data this company holds BEYOND what it already monetises — the dormant surplus we can unlock. A company can sell some insights AND still sit on a far larger dormant asset. - ICP Audit92
✓ 良好目标 — Celonic 是一家生物制品 CDMO，其核心业务是合同制造和开发服务；它作为副产品生成有价值的监管和流程数据，使其成为一个强大的潜在数据持有者。问题：主要问题是数据所有权：在客户项目中生成的监管和流程数据可能归各自客户所有，而非 Celonic；该公司是私营的 J. Rettenmaier & Söhne (JRS Group) 的子公司，这可能会增加谈判的复杂性。[6, 8, 14]
- Deep Qualification85
⚠ 需要审查 — Celonic 是一个典型的数据持有者；作为 CDMO，它在其核心服务之外会产生大量的监管和制造数据。然而，这些数据受到混合所有权和严格的客户保密协议的约束，使得直接转售受到高度限制。[许可受限]
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
Industrial data
这些证据包括来自生物制品 GMP 生产过程的时间序列数据，这对于预测生产结果和验证监管申报的工艺一致性的人工智能模型至关重要。
business_records
这些证据证实了专有 CHOvolution® 细胞系的性能记录的所有权，这是一个用于训练人工智能理解特定高性能表达平台细微差别的独特数据集。
Regulatory records
这些基于文本的证据包括用于 ATMP 的广泛质量控制和分析数据集，为训练监管人工智能处理先进疗法所需的复杂文档提供了宝贵的语料库。
Marketplace
Dataset details
Detailed schema & sample available on access request.
Want this data?
Request access — we broker a secure deal room. Operator-reviewed, no automatic sharing.
This listing was generated automatically from public signals. It is not verified, and we are not affiliated with this company.
Coverage
Scanned sources
Deliverable
Premium dataset report
Celonic Regulatory Records — a Moderate regulatory records dataset (Text modality) in the healthcare domain. Primary AI use-case: Regulatory RAG. Market signal: Global Regulatory Information Management system market = $2.2 billion in 2024, CAGR 10.9% (source: Global Market Insights). [4]. Investment score 62.0/100 (confidence 0.49). Recommended action: Partnership (group-level).
From the marketplace
Explore live data opportunities
Radiantnuclear — 监管记录数据集机会
View opportunity →工业Selva Electronique — 法规记录数据集机会
View opportunity →移动出行Willsonintl — 法规记录数据集机会
View opportunity →